Overexpression of CXCL3 can enhance the oncogenic potential of prostate cancer

PURPOSE - CXCL3 and its receptor CXCR2 were considered to play particularly important roles in the progression of malignancies. However, the investigations about CXCL3/CXCR2 axis in prostate cancer have been poorly involved.

Herein we firstly reported our studies on the expression and biological roles of CXCL3 and CXCR2 in prostate cancer.

METHODS - Expression levels of CXCL3 and CXCR2 in prostate cancer cell lines (PC-3, DU145 and LNCaP), immortalized prostate stromal cell line (WPMY-1) and immortalized prostate epithelial cell line (RWPE-1) were investigated by RT-PCR, ELISA and western blot, whereas expression levels of CXCL3 in a prostate tissue microarray were detected by immunohistochemistry. Cell counting kit-8 and transwell assays were, respectively, utilized to determine the effects of exogenous CXCL3 on the cell proliferation and migration. We further examined whether CXCL3 could regulate the expression of genes correlated with prostate tumorigenesis by RT- PCR.

RESULTS - Elevated expression of CXCR2 was detected in DU145, LNCaP and RWPE-1. Moreover, high-level CXCL3 can be secreted by PC-3 and RWPE-1, and CXCL3 protein expression level in tissue microarray is concordant with prostate cancer metastasis. Exogenous CXCL3 does not contribute to proliferation, but has a significant effect on migration of prostate cancer cells and RWPE-1. Finally, our data showed that exogenous CXCL3 can regulate the expression of genes including ERK, TP73, NUMB, BAX and NDRG3.

CONCLUSIONS - Our findings suggest that CXCL3 and its receptor CXCR2 are overexpressed in prostate cancer cells, prostate epithelial cells and prostate cancer tissues, which may play multiple roles in prostate cancer progression and metastasis.

International urology and nephrology. 2016 Feb 02 [Epub ahead of print]

Shi-Liang Gui, Li-Chen Teng, Shu-Qiu Wang, Shuang Liu, Ying-Li Lin, Xiao-Lian Zhao, Lei Liu, Hong-Yu Sui, Yang Yang, Li-Chun Liang, Mo-Lin Wang, Xin-Yi Li, Yu Cao, Feng-Ying Li, Wei-Qun Wang

Department of Urology, The First Affiliated Hospital, Jiamusi University, Jiamusi, Heilongjiang, China. , Department of Urology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Department of Urology, Affiliated Xuzhou Hospital of Jiangsu University (Xuzhou Cancer Hospital), Xuzhou, Jiangsu, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China. , Basic Medical College, Jiamusi University, Jiamusi, Heilongjiang, China.  

PubMed